BMI

Slim Pickings: Finding Cost-Effective Obesity Solutions

Retrieved on: 
Monday, January 8, 2024

NEW YORK, Jan. 8, 2024 /PRNewswire-PRWeb/ -- During the Middle Ages and Renaissance, a full figure was a symbol of status, indicating one's wealth, fertility and power in an environment of food scarcity. Today, it has a negative connotation. Faced with antiquity's unreliable resources, humans were hardwired to prioritize calorie-dense, energy-rich foods. To reinforce this behavior, evolution gave a boost of dopamine to big eaters; those who failed to feast during times of plenty might starve when food ran out. While abundant calorie consumption was an advantage in early societies, the ingrained drive to stock up is now a liability as access to food has become more reliable.

Key Points: 
  • Obesity presents many health risks, and expensive GLP-1 agonists have grabbed the limelight, but there are affordable and effective ways to address it.
  • While this behavior was a boon during times of food instability, constant consumption of energy dense nourishment now contributes to obesity.
  • Obesity not only increases health risks and reduces quality of life and mobility; but also produces a significant economic impact.
  • This requires alternative approaches and comprehensive efforts that combine cost-effective medications with diet and exercise to reduce excessive obesity rates.

CES 2024: AI-Powered Weight Loss Takes Center Stage as EW2Health Unveils Game-Changing Sinque Technology

Retrieved on: 
Friday, January 5, 2024

THE HAGUE, Netherlands, Jan. 5, 2024 /PRNewswire-PRWeb/ -- EW2Health (Easy Way to Health), a technology company developing innovative, friendly, data-driven solutions for health professionals, today announced plans to showcase Sinque™, its patented behavioral analytics and monitoring solution for weight loss, at CES 2024. EW2Health will demonstrate Sinque as part of the NL Tech Pavilion in Eureka Park, Booth 62100 at the Venetian Expo, from January 9–12, 2024. Additionally, EW2Health will pitch on the CES Startup Stage on Wednesday, January 10, 2–4 p.m., after winning one of the eight coveted pitch spots among more than 50 competing startups. Watch this short video to learn more about Sinque.

Key Points: 
  • EW2Health will demonstrate Sinque as part of the NL Tech Pavilion in Eureka Park, Booth 62100 at the Venetian Expo, from January 9–12, 2024.
  • Sinque benefits weight loss professionals, corporate wellness, health insurance, preventive medicine, and health innovators.
  • The Sinque patented algorithm uses predictive behavioral analytics to learn a user's weight fluctuation patterns and predict their 'true' weight trend.
  • Health professionals use the Sinque technology dashboard to assess individual and group metrics and to gauge adherence, weight trends and weight loss results.

Virta Expands its Provider-led Weight Loss Program to Adults with BMI >25 As Demand Surges for Cost Effective Alternatives to GLP-1 Drugs

Retrieved on: 
Thursday, January 4, 2024

Virta Health, the leader in drug-free clinical weight loss and type 2 diabetes reversal, today announced significant traction against the company’s expansion into weight loss solutions.

Key Points: 
  • Virta Health, the leader in drug-free clinical weight loss and type 2 diabetes reversal, today announced significant traction against the company’s expansion into weight loss solutions.
  • “Virta delivers drug-like impact, without the drugs,” said Dr. Adam Wolfberg, Chief Medical Officer at Virta.
  • For nearly a decade, Virta Health has been de-prescribing GLP-1 drugs while sustaining clinically significant weight loss.
  • Because much of the weight loss is regained once people stop using the drugs, much of the spend on GLP-1s is also therefore wasted.

Use of SGLT2 Inhibitors Continues to Expand for the Treatment of Chronic Kidney Disease, with Eli Lilly/Boehringer Ingelheim’s Jardiance Making Significant Strides Following Label Expansion

Retrieved on: 
Wednesday, January 3, 2024

As the landscape grows more competitive, their role will be crucial in determining the success of brands like Farxiga and Jardiance.

Key Points: 
  • As the landscape grows more competitive, their role will be crucial in determining the success of brands like Farxiga and Jardiance.
  • This unique positioning compared to other agents was swiftly recognized by nephrologists, prompting them to express a clear preference for the brand.
  • Since the label expansion of Eli Lilly/Boehringer Ingelheim's Jardiance to include CKD, nephrologists have rapidly embraced this drug for both their DKD and non-diabetic CKD patients.
  • Several of these agents, including SGLT2 inhibitors and Kerendia, have demonstrated their effectiveness in slowing the progression of CKD.

BioAdaptives, Inc. to Form New Division, AI BodyShape Lab, to Promote Adult Fitness and Weight Management

Retrieved on: 
Thursday, December 21, 2023

LAS VEGAS, NV, Dec. 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioAdaptives Inc. (OTC: BDPT), a leading manufacturer and distributor of innovative, all-natural dietary supplements, announces the formation of a new business division, AI BodyShape Lab, in January 2024 to promote adult fitness and weight management.

Key Points: 
  • LAS VEGAS, NV, Dec. 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioAdaptives Inc. (OTC: BDPT), a leading manufacturer and distributor of innovative, all-natural dietary supplements, announces the formation of a new business division, AI BodyShape Lab, in January 2024 to promote adult fitness and weight management.
  • AI BodyShape Lab is positioned to optimize BioAdaptives’ patented, AI-based ‘Fit Your Outfit’ smartphone application for those who desire to monitor and improve their body composition.
  • In addition to offering state-of-the-art monitoring, AI BodyShape Lab will provide dietary information, suggested dietary meal replacements, and a variety of exercises for adults.
  • Fit Your Outfit works with a cellphone photo to calculate precise body measurements that can be used to document and track the progress of individuals involved in fitness or weight management activities.”

Fractyl Health Announces New Pooled Analysis From Revita® Clinical Studies Demonstrating Initial Weight Loss and Sustained Weight Maintenance Without Weight Regain Through at Least One Year Post-Revita Procedure

Retrieved on: 
Thursday, December 14, 2023

LEXINGTON, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Fractyl Health, a metabolic therapeutics company focused on pioneering new approaches for the treatment of type 2 diabetes (T2D) and obesity, presented new weight maintenance data from a pooled analysis of subjects enrolled in Revita clinical studies across the EU and US. The analysis interrogated patterns of weight change (a prespecified secondary endpoint in all included trials) in patients with inadequately controlled T2D on multiple glucose-lowering agents who have been followed through at least 48 weeks post-treatment with Revita.

Key Points: 
  • 157 participants were included in the analysis, with an average baseline weight of 93 kg and a mean BMI of 31.
  • Patients were on average 57 years of age with a T2D duration of 10 years and baseline HbA1c of 8.3%.
  • 118 of these subjects underwent Revita, and another 39 underwent a sham endoscopy procedure.
  • “We therefore need interventions to help maintain weight loss in patients who cannot remain on chronic pharmacotherapy for the duration of their lives.

LifeMD and Medifast Partner to Offer Transformative Weight Management Solution

Retrieved on: 
Wednesday, December 13, 2023

NEW YORK, Dec. 13, 2023 (GLOBE NEWSWIRE) --  LifeMD, Inc.TM (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced a strategic alliance with Medifast (NYSE: MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA®. Under the terms of the agreement, Medifast will utilize LifeMD’s virtual care technology platform to provide OPTAVIA Clients access to a clinically supported weight management program, including GLP-1 medications. This collaboration further establishes LifeMD in a market that is projected to reach $100 billion by 2030.1 In addition, LifeMD will have the ability to offer its patients an independent OPTAVIA Coach and other lifestyle support services as part of its weight management program.

Key Points: 
  • Under the terms of the agreement, Medifast will utilize LifeMD’s virtual care technology platform to provide OPTAVIA Clients access to a clinically supported weight management program, including GLP-1 medications.
  • This collaboration further establishes LifeMD in a market that is projected to reach $100 billion by 2030.1 In addition, LifeMD will have the ability to offer its patients an independent OPTAVIA Coach and other lifestyle support services as part of its weight management program.
  • This collaboration is intended to create a comprehensive, accessible, and coordinated approach to combating the escalating obesity public health crisis.
  • Together, Medifast and LifeMD expect to offer a comprehensive health offering starting with weight management, built around a powerful model of support that includes an independent OPTAVIA Coach and a board-certified affiliated clinician.

Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes in a Poster Presentation at the World Congress Insulin Resist

Retrieved on: 
Friday, December 8, 2023

REDWOOD CITY, Calif., Dec. 08, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced the poster presentation of long-term 26 weeks follow-up data from the first two cohorts of adults with type 2 diabetes (T2D) enrolled in the ongoing Phase II clinical study (COVALENT-111) and data from preclinical ex-vivo human islet experiments of BMF-219, the company’s investigational oral covalent menin inhibitor.

Key Points: 
  • “Our goal with BMF-219 is to create a short-term treatment regimen for patients with diabetes that results in long term glycemic control.
  • These early clinical results of improved glycemic control over time while patients are off treatment have been very impressive.
  • Phase II consists of multiple ascending dose (MAD) cohorts and includes adult patients with type 2 diabetes uncontrolled by current therapies.
  • Additional information about the Phase I/II clinical trial of BMF-219 in type 2 diabetes can be found at ClinicalTrials.gov using the identifier NCT05731544.

Rhythm Pharmaceuticals Announces Updates on MC4R Pathway Programs at R&D Event

Retrieved on: 
Wednesday, December 6, 2023

-- Company to host R&D webcast today at 8:00 a.m. ET--

Key Points: 
  • “Today, we are excited to showcase our commitment to understanding the MC4R pathway and developing the next generation of therapies,” said David Meeker, M.D., Chair, President and Chief Executive Officer of Rhythm.
  • The hyperphagia and severe obesity of rare genetically-caused MC4R pathway diseases can present early in life, and these data show potential efficacy in patients younger than 6.
  • A live webcast of the R&D call will be available under "Events and Presentations" in the Investor Relations section of the Rhythm Pharmaceuticals website at https://ir.rhythmtx.com/ .
  • The archived webcast will be available on Rhythm Pharmaceuticals’ website approximately two hours after the conference call and will be available for 30 days following the call.

Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide

Retrieved on: 
Thursday, November 30, 2023

GAITHERSBURG, Md., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company (the “Company”), today announced topline results from its 48-week MOMENTUM Phase 2 obesity trial of pemvidutide. The trial enrolled 391 subjects with obesity or overweight with at least one co-morbidity and without diabetes. Subjects were randomized 1:1:1:1 to 1.2 mg, 1.8 mg, 2.4 mg pemvidutide or placebo administered weekly for 48 weeks in conjunction with diet and exercise. The 1.2 mg and 1.8 mg doses were administered without dose titration, while a short 4-week titration period was employed for the 2.4 mg dose. At baseline, subjects had a mean age of approximately 50 years, mean body mass index (BMI) of approximately 37 kg/m2 and mean body weight of approximately 104 kg. Approximately 75% of subjects were female.

Key Points: 
  • The trial enrolled 391 subjects with obesity or overweight with at least one co-morbidity and without diabetes.
  • Subjects were randomized 1:1:1:1 to 1.2 mg, 1.8 mg, 2.4 mg pemvidutide or placebo administered weekly for 48 weeks in conjunction with diet and exercise.
  • More subjects receiving pemvidutide stayed on study compared to those receiving placebo, with 74.1% of pemvidutide subjects completing the trial compared to 61.9% of placebo subjects.
  • If approved, we believe pemvidutide could offer an important option for obesity patients, including those with risk factors for cardiovascular disease.”